NCT02068235View on ClinicalTrials.gov

Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy
Interventions
DRUG

Ponesimod 5mg i.v.

DRUG

Ponesimod i.v.

Dose and infusion rate will be adjusted according to the results of the pilot phase

DRUG

Ponesimod 10 mg tablet

Trial Locations (1)

CF48 4DR

Simbec Research Limited, Merthyr Tydfil

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY